Amalgamated Bank Sells 820 Shares of DaVita Inc. $DVA

Amalgamated Bank trimmed its stake in shares of DaVita Inc. (NYSE:DVA) by 8.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,761 shares of the company’s stock after selling 820 shares during the period. Amalgamated Bank’s holdings in DaVita were worth $1,248,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. National Pension Service lifted its holdings in DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company’s stock worth $30,000 after buying an additional 84 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Y.D. More Investments Ltd bought a new position in DaVita in the first quarter valued at about $35,000. Mid American Wealth Advisory Group Inc. acquired a new stake in DaVita in the second quarter worth about $36,000. Finally, Ameritas Advisory Services LLC bought a new stake in DaVita during the 2nd quarter worth about $47,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DVA stock opened at $121.55 on Friday. DaVita Inc. has a 52 week low of $115.39 and a 52 week high of $179.60. The company’s 50 day moving average price is $129.43 and its two-hundred day moving average price is $136.06. The company has a market capitalization of $8.58 billion, a P/E ratio of 12.52, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last released its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on DVA shares. Truist Financial set a $140.00 target price on shares of DaVita in a research note on Tuesday, October 14th. Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Monday. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a research report on Wednesday, October 8th. TD Cowen cut their price target on DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research note on Monday. Finally, Barclays decreased their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $148.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.